INSPIRE-COPD-ENCT07275359
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
At risk: Primary completion moved 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 1, 2026 to Feb 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 17 words
- Primary completion pushed from Sep 1, 2028 to Feb 1, 2029
- Study completion pushed from Oct 2, 2029 to Oct 1, 2030
- Site contact updated
- Notable Primary completion pushed from Mar 31, 2027 to Sep 1, 2028
- Study completion pushed from Sep 30, 2027 to Oct 2, 2029
- Notable Start date: Mar 1, 2026 to Sep 1, 2026
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Determine feasibility of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine acceptability of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine safety of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Determine tolerability of metformin administration in older persons with COPD without diabetes
Timeframe: 6 months
Arms and interventions
MetforminExperimental
Metformin in COPD patients without diabetes
Drugs: Metformin
Sites
1 site in 1 country
- Duke Asthma, Allergy, and Airway CenterDurham, North Carolina, United States